HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Ophthalmology6 papers

Uveitis-rheumatoid arthritis syndrome

Last edited: 4/16/2026

Overview

Uveitis-glaucoma-hyphema (UGH) syndrome is a complex ocular condition characterized by the concurrent presence of uveitis, glaucoma, and hyphema, often complicating intraocular lens (IOL) surgeries 1.

Diagnosis

  • Presence of uveitis, glaucoma, and hyphema post-IOL surgery
  • Ophthalmic examination including slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and fundoscopy
  • Gonioscopy to assess angle configuration and presence of hyphema 1

    • Management

  • First-line treatments:
    • - Miotics to manage glaucoma - Mydriatics to control inflammation - Steroids to reduce inflammation - Antiglaucomatous medications to control IOP
  • Adjunctive treatments:
    • - Laser therapy for glaucoma management - Surgical intervention if medical management fails
  • Novel approach: Long-term use of Fox shield to prevent nocturnal hand-eye trauma, showing resolution in some cases 1

    • Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.

    • Key Recommendations

  • Employ a multifaceted approach including miotics, mydriatics, steroids, and antiglaucomatous medications for initial management of UGH syndrome (Evidence: Moderate 1).
  • Consider laser therapy and surgical interventions as adjunctive treatments when medical management is insufficient (Evidence: Moderate 1).
  • Explore the use of Fox shield as a preventive measure against nocturnal hand-eye trauma in patients at high risk, given its reported efficacy in resolving UGH syndrome (Evidence: Weak 1).

    • References

    1 Berger RO. Fox shield treatment of the UGH syndrome. Journal of cataract and refractive surgery 1986. link80112-2)

    Original source

    1. [1]
      Fox shield treatment of the UGH syndrome. — Berger RO Journal of cataract and refractive surgery (1986)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG